Summary: Abbott’s Alere NT-proBNP assay for the Alinity i system offers a new tool for diagnosing heart failure, providing accurate results with improved lab efficiency.

Takeaways:

  1. Enhanced Diagnostic Tool: The Alere NT-proBNP assay aids in diagnosing heart failure by measuring NT-proBNP levels, a critical biomarker linked to cardiac stress.
  2. Laboratory Efficiency: Designed for the Alinity i system, the assay offers streamlined workflows with features like 30-day reagent stability and minimal calibration requirements.
  3. Broader Cardiac Portfolio: This addition strengthens Abbott’s cardiac testing capabilities, integrating seamlessly with the Alinity ci system for comprehensive clinical chemistry and immunoassay needs.

The U.S. Food and Drug Administration (FDA) announced the clearance of a test from Abbott that assesses cardiac function in people with heart failure. Heart failure accounts for roughly one million emergency department visits in the U.S. each year.

The Alere NT-proBNP assay for Alinity i offers a new choice for aiding in the diagnosis of heart failure. This test offers an accurate, reliable result with no significant biotin interference, which is critical for physician diagnosis and care, according to the company. Abbott’s Alinity i system ensures efficiency in the lab, supporting assay features like 30-day, on-instrument reagent stability and once-per-lot calibration requirements, helping labs streamline workflows. 

The Biomarker 

N-terminal pro b-type natriuretic peptide (NT-proBNP) is a protein involved in producing B-type natriuretic peptide (BNP), a hormone the body makes when the heart has to work harder than usual to pump blood. In the emergency department, measurements of NT-proBNP are used to help diagnose heart failure in patients with clinical suspicion of new onset or worsening heart failure.

The indication 

The Alere NT-proBNP for Alinity i assay is a chemiluminescent microparticle immunoassay (CMIA) used for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide (NT-proBNP) in human serum and plasma on the Alinity i system.

Abbott’s Platform

The new assay rounds out Abbott’s cardiac menu for its Alinity ci, a system for hospital laboratories that integrates clinical chemistry and immunoassay in one compact system.


Further Reading